Investor News

PHI releases App Suite 2 – more apps and greater applicability

App Suite 2 is the second release in a series of planned App Suite releases, developed to provide automated live-cell studies to researchers worldwide in an unprecedented user-friendly workflow, using PHI’s HoloMonitor-technology.

Read More

Chairman Klas Cramborn has passed away after a period of illness

By reason of chairman Klas Cramborn’s death, the Board of Directors of Phase Holographic Imaging (PHI) has decided to appoint Mats Lundwall as acting chairman of the Board. “Klas has meant a lot to PHI’s development. With his strategic skills in combination integrity and humor Klas has led the Board in a very commendable way

Read More

PHI expands European distributor network

System-c bioprocess, Aurogene and Labsoft have recently been appointed to respectively represent Phase Holographic Imaging (PHI) in France, Italy and Poland.

Read More

Interim Report for the third quarter

For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.

Read More

Leading life science tools company enters technology assessment agreement with PHI

A major publicly traded life science tools company has entered a technology assessment agreement with Phase Holographic Imaging (PHI). The purpose of the agreement is to assess PHI’s Holo¬Monitor technology for cell biology applications, primarily within immuno-oncology.

Read More

PHI and BioSpherix expand marketing partnership after scientific evaluation

In June 2018, Phase Holographic Imaging (PHI) and BioSpherix Medical entered a collaboration agreement, aiming to co-market the companies’ complementary product lines. BioSpherix develops and market advanced hermetically sealed cell incubators for the control and optimization of cell culture environments.

Read More

Cancer researchers use HoloMonitor to track skin cancer cells

Scientists at the Holographic Imaging Cytometry Center of Excellence at University of California, San Francisco, study how normal skin cells transform into aggressive skin cancer. HoloMonitor M4 plays an important role in their research.

Read More

Interim Report for the second quarter

For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.

Read More

Lunds Universitet och PHI samarbetar kring utveckling av nya 3D-cellodlingsmetoder för immunterapiforskning

Baserat på PHI:s befintliga HoloMonitor-teknik, har institutionen för Immun­teknologi vid Lunds Universitet och Phase Holographic Imaging (PHI) avtalat om att gemensamt utveckla nya metoder för 3‑dimensionell cell­odling. Detta för att möta ett akut och snabbt växande behov av dessa metoder inom cancerforskningen.

Read More

Lund University and PHI partner to develop novel 3D cell culturing methods for immunotherapy research

Based on PHI’s current HoloMonitor technology, the Department of Immunotechnology at Lund University and Phase Holographic Imaging (PHI) recently agreed to jointly develop novel 3-dimensional cell culturing methods to meet the urgent need for such methods.

Read More